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Syphilis. The name of this widespread and ancient
disease is familiar to health care providers world-
wide. This name recognition, however, belies the
complexity of the disease, as well as the diagnostic
and therapeutic challenges that continue to affect
global efforts to control syphilis. Early (primary or
secondary) syphilis is typically marked by ulcerative
lesions that occur initially at the site of inoculation,
followed several months later by widespread cuta-
neous, mucosal, and even systemic manifestations
of the dissemination of the causal agent, 
 
Treponema
pallidum 
 
(see Figure 1). Even without treatment, both
primary and secondary lesions resolve, and the in-
fection enters a “latent” stage. During this stage,
there are no clinical manifestations of disease, yet
the infection may still be passed to children born to
infected mothers; it may also progress, resulting in
late (tertiary) manifestations, including late neuro-
syphilis, cardiovascular disease, and space-occu-
pying inflammatory lesions (gumma). The ill effects
of syphilis, however, go far beyond the disease’s
effect on individual infected persons. Early syphi-
lis is associated with the infection of sexual part-
ners and an increased risk of acquisition or trans-
mission of human immunodeficiency virus (HIV).
The transmission of syphilis to infants of untreat-
ed mothers may occur at any stage of infection.
The disease remains a public health problem
worldwide. The World Health Organization (WHO)
estimates that there are 12 million new cases of
syphilis each year, with more than 90 percent oc-
curring in developing nations (see Figure 2). Con-
genital syphilis remains a leading cause of stillbirths
and death among neonates in many developing
countries. In Russia and much of Eastern Europe,
the reemergence of syphilis is contributing to bur-
geoning HIV epidemics. In North America and
Western Europe, where the disease is less common,
the epidemiology of syphilis has shifted so that
the infection is disproportionately common among
men who have sex with men and persons who use
cocaine or other illicit drugs; in these regions, the
rates of infection are again rapidly increasing.
Despite dramatic advances in other biomedical
fields, the tools for the management and control of
syphilis have changed little in the past 60 years. Al-
though they are effective for many infected persons,
these tools — serologic testing, penicillin therapy,
and a clinic-based infrastructure for the control of
sexually transmitted diseases — have limitations.
Addressing these limitations could enhance syphi-
lis-control efforts. 
It is not practical to cultivate 
 
T. pallidum
 
 for di-
agnostic purposes. Dark-field microscopy is not
widely available and can be performed only in the
small proportion of infected persons who have le-
sions. Consequently, serologic testing, used both
in screening for asymptomatic infections and as
an adjunct to clinical diagnosis, remains the princi-
pal tool for the diagnosis of syphilis, as it has been
since the 1930s. Although relatively simple, inex-
pensive, and sensitive tests are commercially avail-
able, a major limitation is the inability to perform
serologic testing easily on site and provide treat-
ment during the same clinic visit. Furthermore,
serologic diagnosis and follow-up may be con-
founded by false positive tests and a slow serologic
response to therapy; it has been observed that one
year after the receipt of recommended penicillin
therapy, more than 15 percent of patients with early
syphilis do not have serologic evidence of a thera-
peutic response, despite the resolution of clinical
manifestations of infection. 
The Sexually Transmitted Diseases Diagnos-
tics Initiative of the WHO is currently conducting
field evaluation of four rapid, point-of-care sero-
logic tests for syphilis that were found to provide
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Figure 1. 
 
Treponema pallidum 
 
in a Skin-Biopsy Specimen 
(Steiner Silver Stain).
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reproducible and accurate results with the use of
whole-blood specimens. These tests cost less than
$1 apiece, are simple to perform, and require min-
imal training and no equipment. Effective point-
of-care tests of this sort could substantially enhance
control efforts in many settings by improving the
screening of pregnant women before childbirth
and the on-site testing of patients with suspicious
clinical lesions, and thereby facilitating the timely
treatment of infected persons.
Few of the newer antibiotics have been studied
extensively as possible syphilis therapies. In the ear-
ly 1940s, syphilis was among the first infections
to be treated with penicillin. At present, long-act-
ing (benzathine) penicillin remains the best-stud-
ied drug and is the only medication that is routinely
recommended for patients with syphilis who are
not allergic to penicillin. Effective single-dose oral
therapy could enhance syphilis control, particular-
ly if it were used in combination with accurate, rap-
id, point-of-care diagnostic tests. The pharmaco-
logic properties of azithromycin and data from
small case series suggest that this drug may be a
promising alternative for syphilis therapy. Howev-
er, as described by Lukehart and coworkers in this
issue of the 
 
Journal 
 
(pages 154–158), there are case
reports of treatment failures, and a genetic muta-
tion of 
 
T. pallidum
 
 has been associated with resis-
tance to macrolides and related antibiotics. There-
fore, azithromycin use is not recommended unless
careful follow-up can be ensured. The National In-
stitute of Allergy and Infectious Diseases is spon-
soring an ongoing randomized clinical trial com-
paring azithromycin with benzathine penicillin for
the treatment of early syphilis; the trial will provide
data on the usefulness of this new drug for syphilis
therapy.
Finally, clinic-based efforts to eliminate the dis-
ease have not succeeded. Syphilis persists in devel-
oping nations and is resurging in parts of the world
where the rates of disease were once lower. Simple,
affordable tools for diagnosis and curative therapy
are already available. The absence of a sound health
care infrastructure has been cited as another miss-
ing link in syphilis-control efforts. Many infants in
developing nations still die of congenital syphilis,
despite the fact that current serologic tests cost less
than 50 cents and one dose of benzathine penicil-
lin costs 23 cents. The combination of rapid on-site
testing and oral treatment may offer a viable solu-
tion for decentralized, primary care–based syphi-
lis-control programs. Point-of-care serologic tests
could be provided for at-risk persons wherever they
might be found. A single-dose oral regimen will be
 
Figure 2. Estimated Annual Number of New Cases of Syphilis among Adults.
 
Data are from the World Health Organization for 1999 (www.who.int/docstore/hiv/GRST1/pdf/figure09.pdf).
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preferable to one that requires injection. This com-
bined approach could be considered for use in out-
breaks as well.
Syphilis remains a worthy target for biomedi-
cal research. There are still important unanswered
questions about the organism, the disease, and
appropriate management strategies. Modern ap-
proaches to the understanding of the pathogenesis
of syphilis, the development of improved diagnos-
tic tests, and the implementation of decentralized
management strategies offer the promise of im-
proving syphilis control. Although some progress
has been made, questions remain about the man-
agement of long-standing latent infections, central
nervous system involvement, and the interaction
between syphilis and HIV. Answers and solutions
are urgently needed.
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